Table 4 Relationships between Polymorphisms of SLC19A1, FPGS, or GGH and adverse events stratified by genotype.

From: Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis

  

genotype

AE(−) group

AE (+) group

P value

SLC19A1

rs1051266

80G > A

GG/AG/AA

GG/AG/AA

p = 0.139

68/93/27

26/37/20

FPGS

rs10106

1994A > G

AA/AG/GG

AA/AG/GG

p = 0.952

91/78/19

39/37/7

rs1054774

11694T > A

TT/AT/AA

TT/AT/AA

p = 0.289

73/89/26

40/38/10

rs1544105

2572C > T

CC/CT/TT

CC/CT/TT

p = 0.327

93/80/15

35/40/8

GGH

rs719235

452C > T

CC/CT/TT

CC/CT/TT

p = 0.688

151/32/5

65/15/3

rs1800909

−401C > T

CC/CT/TT

CC/CT/TT

p = 0.477

7/22/159

5/14/64

rs3758149

−354G > T

GG/GT/TT

GG/GT/TT

p = 0.125

121/61/6

56/23/4

rs11545078

16T > C

TT/CT/CC

TT/CT/CC

p = 0.582

163/25/0

70/12/1

rs12681874

14269G > A

GG/AG/AA

GG/AG/AA

p = 0.174

61/92/39

20/42/21

  1. p values for comparisons between the AE (+) and AE (−) groups were evaluated by the Kruskal-Wallis test.
  2. SLC19A1: reduced folate carrier 1, FPGS: folylpolyglutamyl synthase, GGH: gamma-glutamyl hydrolase.